Last week, James Cox, CEO, and Jason Beckwith, VP Talent Science & Thought Leadership, attended and spoke at the Sachs Associates CEO Forum in Zurich, presenting on Predictive Workforce Dynamics for Biopharma. It was a fantastic opportunity to share insights on how workforce trends are shaping the future of the industry, and to connect with leaders around investment trends, talent strategy, and the future of biopharma.
During the event, one theme became clear: across seed and Series A biotech pitches, three elements dominated almost every conversation, intellectual property, strategy, and talent. IP is straightforward. Investors can assess patents, evaluate their strength, and assign value. Strategy is also measurable: target indications, market size, and development pathways can be modelled and valued.
Talent, however, remains the most challenging and least quantified element. Most presentations included the same qualitative slide, photos of the leadership team, “20+ years of experience,” and logos of previous companies. While visually appealing, this approach tells investors very little about whether the team can execute the strategy effectively.
IP has an asset value. Strategy has an asset value. Talent should too.
At BioTalent, Talent Science provides a way to quantify what has traditionally been qualitative. By measuring workforce architecture, leadership capability, and organisational design, we help biotech leaders demonstrate their ability to execute strategy with greater clarity. For investors, it offers a deeper view of whether a team has the structure and capability required to deliver on the science.
If you’re preparing for investment or evaluating early stage opportunities and want to better understand how Talent Science can help quantify execution capability, Get in touch with the BioTalent team to continue the conversation.